NASDAQ:ATRC AtriCure Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $43.65 +1.04 (+2.44%) (As of 07/7/2022 12:28 PM ET) Add Compare Share Today's Range$42.24▼$43.9950-Day Range$35.10▼$54.7552-Week Range$32.83▼$89.18Volume1,705 shsAverage Volume291,895 shsMarket Capitalization$2.02 billionP/E Ratio38.97Dividend YieldN/APrice Target$83.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AtriCure MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside91.1% Upside$83.20 Price TargetShort InterestBearish5.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 4 Articles This WeekInsider TradingSelling Shares$154,104 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.07) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.01 out of 5 starsMedical Sector460th out of 1,433 stocksSurgical & Medical Instruments Industry56th out of 137 stocks 3.4 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $83.20, AtriCure has a forecasted upside of 91.1% from its current price of $43.53.Amount of Analyst CoverageAtriCure has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.17% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in AtriCure has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 1.8 News and Social Media Coverage News SentimentAtriCure has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AtriCure this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $154,104.00 in company stock.Percentage Held by InsidersOnly 2.80% of the stock of AtriCure is held by insiders.Percentage Held by Institutions95.36% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($1.07) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is 38.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 95.40.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is 38.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 73.92.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address About AtriCure (NASDAQ:ATRC) StockAtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More ATRC Stock News HeadlinesJuly 6, 2022 | finance.yahoo.comCardiac Arrhythmia Monitoring Devices Market to Grow by a Substantial CAGR of 6.33% by 2027, As per DelveInsight - Yahoo FinanceJuly 4, 2022 | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 1, 2022 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Upgraded to Hold at StockNews.comJune 28, 2022 | benzinga.comAnalyst Ratings for AtriCure - Benzinga - BenzingaJune 27, 2022 | businesswire.comGlobal Coronary Artery Bypass Graft Surgery Pipeline Report 2022 Update - ResearchAndMarkets.com - Business WireJune 24, 2022 | benzinga.comBTIG Maintains Buy on AtriCure, Lowers Price Target to $75 - Benzinga - BenzingaJune 18, 2022 | finance.yahoo.comIs It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)? - Yahoo FinanceJune 18, 2022 | finance.yahoo.comIs It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?June 12, 2022 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Hits New 12-Month Low at $38.26June 8, 2022 | businesswire.comGlobal Atrial Fibrillation Market Research Report 2022: Treatment Types and End-User Facilities - Forecast to 2027 - ResearchAndMarkets.com - Business WireJune 7, 2022 | businesswire.comAtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial - Business WireJune 7, 2022 | finance.yahoo.comAtriCure Announces the First Patient Treated in the HEAL-IST Clinical TrialJune 6, 2022 | theglobeandmail.comAtriCure Announces the Appointment of Deborah Yount as Chief Human Resources OfficerJune 1, 2022 | businesswire.comAtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer - Business WireMay 27, 2022 | nasdaq.comAtriCure - For A Healthy HeartMay 26, 2022 | rttnews.comAtriCure - For A Healthy Heart - RTTNewsMay 19, 2022 | benzinga.comRadio Frequency Ablation Devices Market to reach 10.72 Billion in 2030 with a CAGR of around 11.73 % asse - BenzingaMay 9, 2022 | bizjournals.comOne region's top-funded startups closes $7M loan from Silicon Valley Bank - The Business JournalsMay 4, 2022 | benzinga.comAtriCure's Q1 EPS Miss Estimates, Needham Lowers Price TargetMay 4, 2022 | benzinga.com4 Analysts Have This to Say About AtriCure - Benzinga - BenzingaMay 4, 2022 | benzinga.comSVB Leerink Maintains Outperform on AtriCure, Lowers Price Target to $75 - Benzinga - BenzingaMay 3, 2022 | greenwichtime.comAtriCure: Q1 Earnings Snapshot - Greenwich TimeMay 3, 2022 | finance.yahoo.comAtriCure Reports First Quarter 2022 Financial Results - Yahoo FinanceMay 3, 2022 | marketwatch.comAbiomed Inc. stock rises Tuesday, still underperforms market - MarketWatchMay 3, 2022 | investing.comAtriCure Misses Q1 EPS by 1c By Investing.com - Investing.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees875Year Founded2000Company Calendar Last Earnings5/03/2022Today7/07/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$83.20 High Stock Price Forecast$110.00 Low Stock Price Forecast$55.00 Forecasted Upside/Downside+90.6%Consensus RatingModerate Buy Rating Score (0-4)2.8 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.12 Trailing P/E Ratio38.97 Forward P/E RatioN/A P/E GrowthN/ANet Income$50.20 million Net Margins17.93% Pretax Margin18.00% Return on Equity-11.66% Return on Assets-8.44% Debt Debt-to-Equity Ratio0.15 Current Ratio4.21 Quick Ratio3.35 Sales & Book Value Annual Sales$274.33 million Price / Sales7.37 Cash Flow$0.98 per share Price / Cash Flow44.69 Book Value$10.53 per share Price / Book4.15Miscellaneous Outstanding Shares46,290,000Free Float44,992,000Market Cap$2.02 billion OptionableOptionable Beta1.15 Social Links AtriCure Frequently Asked Questions Should I buy or sell AtriCure stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AtriCure stock. View analyst ratings for AtriCure or view top-rated stocks. What is AtriCure's stock price forecast for 2022? 5 Wall Street research analysts have issued 1 year price objectives for AtriCure's shares. Their ATRC stock forecasts range from $55.00 to $110.00. On average, they anticipate AtriCure's share price to reach $83.20 in the next year. This suggests a possible upside of 90.6% from the stock's current price. View analysts' price targets for AtriCure or view top-rated stocks among Wall Street analysts. How has AtriCure's stock price performed in 2022? AtriCure's stock was trading at $69.53 on January 1st, 2022. Since then, ATRC shares have decreased by 37.2% and is now trading at $43.65. View the best growth stocks for 2022 here. When is AtriCure's next earnings date? AtriCure is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for AtriCure. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings data on Tuesday, May, 3rd. The medical device company reported ($0.33) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.33). The medical device company earned $74.58 million during the quarter, compared to the consensus estimate of $71.17 million. AtriCure had a net margin of 17.93% and a negative trailing twelve-month return on equity of 11.66%. The business's quarterly revenue was up 25.8% compared to the same quarter last year. During the same period last year, the business posted ($0.32) EPS. View AtriCure's earnings history. What guidance has AtriCure issued on next quarter's earnings? AtriCure issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of -$1.12--$1.07 for the period, compared to the consensus estimate of -$1.05. The company issued revenue guidance of $318.00 million-$330.00 million, compared to the consensus revenue estimate of $321.65 million. Who are AtriCure's key executives? AtriCure's management team includes the following people: Mr. Michael H. Carrel, CEO, Pres & Director (Age 51, Pay $1.94M)Ms. Angela L. Wirick CPA, Chief Financial Officer (Age 44, Pay $694.64k) (LinkedIn Profile)Mr. Douglas J. Seith, Chief Operating Officer (Age 56, Pay $1.17M) (LinkedIn Profile)Dr. Vinayak Doraiswamy Ph.D., Chief Scientific Officer (Age 50, Pay $777.66k) (LinkedIn Profile)Mr. Justin J. Noznesky, Chief Marketing & Strategy Officer (Age 44, Pay $700.74k) (LinkedIn Profile)Mr. Salvatore Privitera J.D., Chief Technical Officer (Age 55) (LinkedIn Profile)Mr. Karl S. Dahlquist C.C.E.P., CCEP, J.D., Chief Legal & Compliance Officer (Age 52)Valerie Storch-Willhaus, VP of Corp. Marketing & CommunicationsMs. Deborah Yount, Chief HR OfficerMs. Tonya A. Austin SPHR, Sr. VP of HR (Age 50) What is Michael Carrel's approval rating as AtriCure's CEO? 25 employees have rated AtriCure CEO Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of AtriCure's key competitors? Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Abiomed (ABMD). View all of ATRC's competitors. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT). What is AtriCure's stock symbol? AtriCure trades on the NASDAQ under the ticker symbol "ATRC." How do I buy shares of AtriCure? Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AtriCure's stock price today? One share of ATRC stock can currently be purchased for approximately $43.65. How much money does AtriCure make? AtriCure (NASDAQ:ATRC) has a market capitalization of $2.02 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or $1.12 on an earnings per share basis. How many employees does AtriCure have? AtriCure employs 875 workers across the globe. Does AtriCure have any subsidiaries? The following companies are subsidiares of AtriCure: SentreHEART.Read More When was AtriCure founded? AtriCure was founded in 2000. How can I contact AtriCure? AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for AtriCure is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567. This page (NASDAQ:ATRC) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
